Exploration of Individualized Pharmacological Treatment and Prevention Strategies for Migraine
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i4.4817
Abstract
Migraine is a common primary headache disorder characterized by recurrent moderate to severe throbbing pain, often accompanied by nausea, vomiting, and photophobia. Its complex pathogenesis and significant individual differences lead to varying responses to conventional pharmacological treatments, making individualized treatment an important direction in clinical practice. This paper first reviews the pathological and physiological mechanisms of migraine, focusing on the roles of neurovascular regulation disorders, neurotransmitter imbalances, and genetic factors. Then, it explores individualized pharmacological treatment strategies from the perspectives of acute attack treatment and preventive treatment, aims to provide theoretical support and clinical reference for improving the efficacy of migraine treatment and reducing the recurrence rate.
Keywords
migraine; Individualized treatment; pharmacological therapy; prevention strategy; neurotransmitter
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1] Askar G, Askar O, Altuhafy M, et al. Efficacy of prophylactic sodium valproate in pediatric migraines: a systematic review of randomized clinical studies. [J]. Translational pediatrics, 2024, 13 (12): 2254-2266. DOI:10.21037/TP-24-279.
[2] Blumenfeld M A, Mechtler L, Cook L, et al. Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review. [J]. Pain and therapy, 2024, 14 (1): 1-4. DOI:10.1007/S40122-024-00692-5.
[3] Pellesi L, Azorin G D, Beltrán R E, et al. Combining treatments for migraine prophylaxis: the state-of-the-art. [J]. The journal of headache and pain, 2024, 25 (1): 214. DOI:10.1186/S10194-024-01925-W.
[4] Edvinsson L. Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence. [J]. Expert review of neurotherapeutics, 2024, 24 (12): 11-15. DOI:10.1080/14737175.2024.2434079.
[2] Blumenfeld M A, Mechtler L, Cook L, et al. Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review. [J]. Pain and therapy, 2024, 14 (1): 1-4. DOI:10.1007/S40122-024-00692-5.
[3] Pellesi L, Azorin G D, Beltrán R E, et al. Combining treatments for migraine prophylaxis: the state-of-the-art. [J]. The journal of headache and pain, 2024, 25 (1): 214. DOI:10.1186/S10194-024-01925-W.
[4] Edvinsson L. Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence. [J]. Expert review of neurotherapeutics, 2024, 24 (12): 11-15. DOI:10.1080/14737175.2024.2434079.
Copyright © 2026 Xiaoyan Zhang, Changren Li, Muyang Li, Zhenxing Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License